(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 4.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.32%.
Exelixis's revenue in 2024 is $2,013,976,000.On average, 9 Wall Street analysts forecast EXEL's revenue for 2024 to be $586,318,946,641, with the lowest EXEL revenue forecast at $581,120,519,205, and the highest EXEL revenue forecast at $593,012,663,620. On average, 10 Wall Street analysts forecast EXEL's revenue for 2025 to be $598,957,594,820, with the lowest EXEL revenue forecast at $557,952,374,100, and the highest EXEL revenue forecast at $644,954,150,225.
In 2026, EXEL is forecast to generate $665,936,696,613 in revenue, with the lowest revenue forecast at $590,981,671,338 and the highest revenue forecast at $742,102,330,208.